Valuation: Assembly Biosciences, Inc.

Market Cap 506M 445M 414M 380M 713M 48.76B 724M 4.91B 1.92B 23.97B 1.9B 1.86B 82.88B P/E 2026 *
-23.6x
P/E 2027 * -8.91x
Enterprise Value 506M 445M 414M 380M 713M 48.76B 724M 4.91B 1.92B 23.97B 1.9B 1.86B 82.88B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 15.7x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+1.31%
1 week-4.70%
Current month-7.02%
1 month-0.27%
3 months-8.32%
6 months-8.78%
Current year-24.88%
1 week 24.85
Extreme 24.85
27
1 month 24.26
Extreme 24.26
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
17/06/26 Sell

Chief Financial Officer

-29 0.0002%
04/06/26 Free

Chairman

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+1.31%-4.70%+38.48%+93.56% 506M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.33%+0.51%+53.14%+105.84% 24.58B
Weighted average by Cap. +0.48%+0.91%+75.24%+136.55%

Financials

2026 *2027 *
Net sales 45.47M 39.94M 37.14M 34.08M 64.04M 4.38B 65.02M 441M 172M 2.15B 171M 167M 7.44B 32.25M 28.33M 26.34M 24.17M 45.42M 3.11B 46.12M 313M 122M 1.53B 121M 118M 5.28B
Net income -20.46M -17.97M -16.71M -15.34M -28.82M -1.97B -29.26M -198M -77.54M -969M -76.82M -75.16M -3.35B -56.38M -49.52M -46.05M -42.26M -79.4M -5.43B -80.62M -547M -214M -2.67B -212M -207M -9.23B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
24/07/26 $25.55 +1.31% 142,149
23/07/26 $25.22 -3.15% 191,256
22/07/26 $26.04 -1.62% 128,331
21/07/26 $26.47 +5.63% 112,042
20/07/26 $25.06 -6.53% 112,884
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.55USD
Average target price
50.00USD
Spread / Average Target
+95.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock